Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 25.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,793 shares of the biopharmaceutical company’s stock after selling 14,914 shares during the period. SG Americas Securities LLC’s holdings in Lexicon Pharmaceuticals were worth $67,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of Lexicon Pharmaceuticals during the 1st quarter valued at about $26,000. TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $29,000. Kestra Advisory Services LLC bought a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $33,000. ExodusPoint Capital Management LP bought a new position in shares of Lexicon Pharmaceuticals during the 1st quarter valued at about $38,000. Finally, LPL Financial LLC boosted its position in shares of Lexicon Pharmaceuticals by 88.2% during the 2nd quarter. LPL Financial LLC now owns 20,700 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 9,700 shares in the last quarter. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.65 on Friday. Lexicon Pharmaceuticals, Inc. has a one year low of $0.92 and a one year high of $3.79. The company has a 50-day moving average of $2.36 and a two-hundred day moving average of $1.71. The stock has a market cap of $406.30 million, a price-to-earnings ratio of -2.06 and a beta of 1.27. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. On average, equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on LXRX. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Monday, April 15th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, April 11th.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.